|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors |
Vir: |
|
|
|
|
List of services to meet your request
Contains list of services for current record
Basic services |
|
|
Več možnosti |
|
|
© 2024 SFX by Ex Libris Inc. | Piškotki
CrossRef Omogočeno
|